

# Cystic Fibrosis Drugs-EMEA Market Status and Trend Report 2013-2023

<https://marketpublishers.com/r/C5514280CCAEN.html>

Date: November 2017

Pages: 145

Price: US\$ 3,480.00 (Single User License)

ID: C5514280CCAEN

## Abstracts

### Report Summary

Cystic Fibrosis Drugs-EMEA Market Status and Trend Report 2013-2023 offers a comprehensive analysis on Cystic Fibrosis Drugs industry, standing on the readers' perspective, delivering detailed market data and penetrating insights. No matter the client is industry insider, potential entrant or investor, the report will provides useful data and information. Key questions answered by this report include:

Whole EMEA and Regional Market Size of Cystic Fibrosis Drugs 2013-2017, and development forecast 2018-2023

Main market players of Cystic Fibrosis Drugs in EMEA, with company and product introduction, position in the Cystic Fibrosis Drugs market

Market status and development trend of Cystic Fibrosis Drugs by types and applications

Cost and profit status of Cystic Fibrosis Drugs, and marketing status

Market growth drivers and challenges

The report segments the EMEA Cystic Fibrosis Drugs market as:

EMEA Cystic Fibrosis Drugs Market: Regional Segment Analysis (Regional Consumption Volume, Consumption Volume, Revenue and Growth Rate 2013-2023)

Europe

Middle East

Africa

EMEA Cystic Fibrosis Drugs Market: Product Type Segment Analysis (Consumption

Volume, Average Price, Revenue, Market Share and Trend 2013-2023):

Oral  
Injection

EMEA Cystic Fibrosis Drugs Market: Application Segment Analysis (Consumption Volume and Market Share 2013-2023; Downstream Customers and Market Analysis)

Hospitals  
Clinics  
Other

EMEA Cystic Fibrosis Drugs Market: Players Segment Analysis (Company and Product introduction, Cystic Fibrosis Drugs Sales Volume, Revenue, Price and Gross Margin):

Actavis  
F. Hoffmann-La Roche  
Gilead Sciences  
Novartis  
Vertex Pharmaceuticals  
Abbott  
Anthera Pharmaceuticals  
Arcturus Therapeutics  
Boehringer Ingelheim  
Chiesi Farmaceutici  
Corbus Pharmaceuticals  
Genzyme  
Insmed  
Johnson & Johnson  
Merck Sharp & Dohme  
Neovii Biotech  
Novo Nordisk  
PharmaSwiss  
Pharmaxis  
Proteostasis Therapeutics  
PTC Therapeutics  
United Medical  
Venus Remedies

In a word, the report provides detailed statistics and analysis on the state of the industry; and is a valuable source of guidance and direction for companies and individuals interested in the market.

## Contents

### **CHAPTER 1 OVERVIEW OF CYSTIC FIBROSIS DRUGS**

- 1.1 Definition of Cystic Fibrosis Drugs in This Report
- 1.2 Commercial Types of Cystic Fibrosis Drugs
  - 1.2.1 Oral
  - 1.2.2 Injection
- 1.3 Downstream Application of Cystic Fibrosis Drugs
  - 1.3.1 Hospitals
  - 1.3.2 Clinics
  - 1.3.3 Other
- 1.4 Development History of Cystic Fibrosis Drugs
- 1.5 Market Status and Trend of Cystic Fibrosis Drugs 2013-2023
  - 1.5.1 EMEA Cystic Fibrosis Drugs Market Status and Trend 2013-2023
  - 1.5.2 Regional Cystic Fibrosis Drugs Market Status and Trend 2013-2023

### **CHAPTER 2 EMEA MARKET STATUS AND FORECAST BY REGIONS**

- 2.1 Market Status of Cystic Fibrosis Drugs in EMEA 2013-2017
- 2.2 Consumption Market of Cystic Fibrosis Drugs in EMEA by Regions
  - 2.2.1 Consumption Volume of Cystic Fibrosis Drugs in EMEA by Regions
  - 2.2.2 Revenue of Cystic Fibrosis Drugs in EMEA by Regions
- 2.3 Market Analysis of Cystic Fibrosis Drugs in EMEA by Regions
  - 2.3.1 Market Analysis of Cystic Fibrosis Drugs in Europe 2013-2017
  - 2.3.2 Market Analysis of Cystic Fibrosis Drugs in Middle East 2013-2017
  - 2.3.3 Market Analysis of Cystic Fibrosis Drugs in Africa 2013-2017
- 2.4 Market Development Forecast of Cystic Fibrosis Drugs in EMEA 2018-2023
  - 2.4.1 Market Development Forecast of Cystic Fibrosis Drugs in EMEA 2018-2023
  - 2.4.2 Market Development Forecast of Cystic Fibrosis Drugs by Regions 2018-2023

### **CHAPTER 3 EMEA MARKET STATUS AND FORECAST BY TYPES**

- 3.1 Whole EMEA Market Status by Types
  - 3.1.1 Consumption Volume of Cystic Fibrosis Drugs in EMEA by Types
  - 3.1.2 Revenue of Cystic Fibrosis Drugs in EMEA by Types
- 3.2 EMEA Market Status by Types in Major Countries
  - 3.2.1 Market Status by Types in Europe
  - 3.2.2 Market Status by Types in Middle East

- 3.2.3 Market Status by Types in Africa
- 3.3 Market Forecast of Cystic Fibrosis Drugs in EMEA by Types

## **CHAPTER 4 EMEA MARKET STATUS AND FORECAST BY DOWNSTREAM INDUSTRY**

- 4.1 Demand Volume of Cystic Fibrosis Drugs in EMEA by Downstream Industry
- 4.2 Demand Volume of Cystic Fibrosis Drugs by Downstream Industry in Major Countries
  - 4.2.1 Demand Volume of Cystic Fibrosis Drugs by Downstream Industry in Europe
  - 4.2.2 Demand Volume of Cystic Fibrosis Drugs by Downstream Industry in Middle East
  - 4.2.3 Demand Volume of Cystic Fibrosis Drugs by Downstream Industry in Africa
- 4.3 Market Forecast of Cystic Fibrosis Drugs in EMEA by Downstream Industry

## **CHAPTER 5 MARKET DRIVING FACTOR ANALYSIS OF CYSTIC FIBROSIS DRUGS**

- 5.1 EMEA Economy Situation and Trend Overview
- 5.2 Cystic Fibrosis Drugs Downstream Industry Situation and Trend Overview

## **CHAPTER 6 CYSTIC FIBROSIS DRUGS MARKET COMPETITION STATUS BY MAJOR PLAYERS IN EMEA**

- 6.1 Sales Volume of Cystic Fibrosis Drugs in EMEA by Major Players
- 6.2 Revenue of Cystic Fibrosis Drugs in EMEA by Major Players
- 6.3 Basic Information of Cystic Fibrosis Drugs by Major Players
  - 6.3.1 Headquarters Location and Established Time of Cystic Fibrosis Drugs Major Players
  - 6.3.2 Employees and Revenue Level of Cystic Fibrosis Drugs Major Players
- 6.4 Market Competition News and Trend
  - 6.4.1 Merger, Consolidation or Acquisition News
  - 6.4.2 Investment or Disinvestment News
  - 6.4.3 New Product Development and Launch

## **CHAPTER 7 CYSTIC FIBROSIS DRUGS MAJOR MANUFACTURERS INTRODUCTION AND MARKET DATA**

- 7.1 Actavis
  - 7.1.1 Company profile
  - 7.1.2 Representative Cystic Fibrosis Drugs Product

- 7.1.3 Cystic Fibrosis Drugs Sales, Revenue, Price and Gross Margin of Actavis
- 7.2 F. Hoffmann-La Roche
  - 7.2.1 Company profile
  - 7.2.2 Representative Cystic Fibrosis Drugs Product
  - 7.2.3 Cystic Fibrosis Drugs Sales, Revenue, Price and Gross Margin of F. Hoffmann-La Roche
- 7.3 Gilead Sciences
  - 7.3.1 Company profile
  - 7.3.2 Representative Cystic Fibrosis Drugs Product
  - 7.3.3 Cystic Fibrosis Drugs Sales, Revenue, Price and Gross Margin of Gilead Sciences
- 7.4 Novartis
  - 7.4.1 Company profile
  - 7.4.2 Representative Cystic Fibrosis Drugs Product
  - 7.4.3 Cystic Fibrosis Drugs Sales, Revenue, Price and Gross Margin of Novartis
- 7.5 Vertex Pharmaceuticals
  - 7.5.1 Company profile
  - 7.5.2 Representative Cystic Fibrosis Drugs Product
  - 7.5.3 Cystic Fibrosis Drugs Sales, Revenue, Price and Gross Margin of Vertex Pharmaceuticals
- 7.6 Abbott
  - 7.6.1 Company profile
  - 7.6.2 Representative Cystic Fibrosis Drugs Product
  - 7.6.3 Cystic Fibrosis Drugs Sales, Revenue, Price and Gross Margin of Abbott
- 7.7 Anthera Pharmaceuticals
  - 7.7.1 Company profile
  - 7.7.2 Representative Cystic Fibrosis Drugs Product
  - 7.7.3 Cystic Fibrosis Drugs Sales, Revenue, Price and Gross Margin of Anthera Pharmaceuticals
- 7.8 Arcturus Therapeutics
  - 7.8.1 Company profile
  - 7.8.2 Representative Cystic Fibrosis Drugs Product
  - 7.8.3 Cystic Fibrosis Drugs Sales, Revenue, Price and Gross Margin of Arcturus Therapeutics
- 7.9 Boehringer Ingelheim
  - 7.9.1 Company profile
  - 7.9.2 Representative Cystic Fibrosis Drugs Product
  - 7.9.3 Cystic Fibrosis Drugs Sales, Revenue, Price and Gross Margin of Boehringer Ingelheim

## 7.10 Chiesi Farmaceutici

### 7.10.1 Company profile

### 7.10.2 Representative Cystic Fibrosis Drugs Product

### 7.10.3 Cystic Fibrosis Drugs Sales, Revenue, Price and Gross Margin of Chiesi Farmaceutici

## 7.11 Corbus Pharmaceuticals

### 7.11.1 Company profile

### 7.11.2 Representative Cystic Fibrosis Drugs Product

### 7.11.3 Cystic Fibrosis Drugs Sales, Revenue, Price and Gross Margin of Corbus Pharmaceuticals

## 7.12 Genzyme

### 7.12.1 Company profile

### 7.12.2 Representative Cystic Fibrosis Drugs Product

### 7.12.3 Cystic Fibrosis Drugs Sales, Revenue, Price and Gross Margin of Genzyme

## 7.13 Insmed

### 7.13.1 Company profile

### 7.13.2 Representative Cystic Fibrosis Drugs Product

### 7.13.3 Cystic Fibrosis Drugs Sales, Revenue, Price and Gross Margin of Insmed

## 7.14 Johnson & Johnson

### 7.14.1 Company profile

### 7.14.2 Representative Cystic Fibrosis Drugs Product

### 7.14.3 Cystic Fibrosis Drugs Sales, Revenue, Price and Gross Margin of Johnson & Johnson

## 7.15 Merck Sharp & Dohme

### 7.15.1 Company profile

### 7.15.2 Representative Cystic Fibrosis Drugs Product

### 7.15.3 Cystic Fibrosis Drugs Sales, Revenue, Price and Gross Margin of Merck Sharp & Dohme

## 7.16 Neovii Biotech

## 7.17 Novo Nordisk

## 7.18 PharmaSwiss

## 7.19 Pharmaxis

## 7.20 Proteostasis Therapeutics

## 7.21 PTC Therapeutics

## 7.22 United Medical

## 7.23 Venus Remedies

# **CHAPTER 8 UPSTREAM AND DOWNSTREAM MARKET ANALYSIS OF CYSTIC FIBROSIS DRUGS**

- 8.1 Industry Chain of Cystic Fibrosis Drugs
- 8.2 Upstream Market and Representative Companies Analysis
- 8.3 Downstream Market and Representative Companies Analysis

## **CHAPTER 9 COST AND GROSS MARGIN ANALYSIS OF CYSTIC FIBROSIS DRUGS**

- 9.1 Cost Structure Analysis of Cystic Fibrosis Drugs
- 9.2 Raw Materials Cost Analysis of Cystic Fibrosis Drugs
- 9.3 Labor Cost Analysis of Cystic Fibrosis Drugs
- 9.4 Manufacturing Expenses Analysis of Cystic Fibrosis Drugs

## **CHAPTER 10 MARKETING STATUS ANALYSIS OF CYSTIC FIBROSIS DRUGS**

- 10.1 Marketing Channel
  - 10.1.1 Direct Marketing
  - 10.1.2 Indirect Marketing
  - 10.1.3 Marketing Channel Development Trend
- 10.2 Market Positioning
  - 10.2.1 Pricing Strategy
  - 10.2.2 Brand Strategy
  - 10.2.3 Target Client
- 10.3 Distributors/Traders List

## **CHAPTER 11 REPORT CONCLUSION**

## **CHAPTER 12 RESEARCH METHODOLOGY AND REFERENCE**

- 12.1 Methodology/Research Approach
  - 12.1.1 Research Programs/Design
  - 12.1.2 Market Size Estimation
  - 12.1.3 Market Breakdown and Data Triangulation
- 12.2 Data Source
  - 12.2.1 Secondary Sources
  - 12.2.2 Primary Sources
- 12.3 Reference



## I would like to order

Product name: Cystic Fibrosis Drugs-EMEA Market Status and Trend Report 2013-2023

Product link: <https://marketpublishers.com/r/C5514280CCAEN.html>

Price: US\$ 3,480.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

[info@marketpublishers.com](mailto:info@marketpublishers.com)

## Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/C5514280CCAEN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:  
Last name:  
Email:  
Company:  
Address:  
City:  
Zip code:  
Country:  
Tel:  
Fax:  
Your message:

**\*\*All fields are required**

Customer signature \_\_\_\_\_

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970